Teva Gains Global Rights to Polpharma Biologics' Ocrevus Biosimilar

Teva Pharmaceutical Industries Ltd and Polpharma Biologics International AG have executed a global licensing agreement under which Teva obtains exclusive rights to market Polpharma Biologics' proposed biosimilar to Ocrevus (ocrelizumab), contingent on regulatory clearance. The deal covers both formulations of the candidate.

Ocrevus is a monoclonal antibody approved for treatment of multiple sclerosis. The licensing structure pairs Polpharma Biologics' biosimilar development capabilities with Teva's established commercial infrastructure and market access across territories.

The agreement represents a significant expansion of Teva's immunology portfolio in the biosimilar space. By securing global rights rather than regional distribution, Teva positions itself to capture market share across developed and emerging markets as Ocrevus' patent protections erode. The exclusive arrangement eliminates competitive pressure from other biosimilar entrants in this therapeutic category.

Polpharma Biologics retains development responsibility through regulatory approval. Upon achieving licensure, Teva assumes full commercialization duties, including manufacturing partnerships, regulatory interactions with health authorities, and go-to-market execution across all territories worldwide.

The multiple sclerosis market represents a high-value category for biosimilar penetration, with substantial patient populations in North America, Europe, and Asia-Pacific. Ocrevus generated significant revenues prior to biosimilar competition, making the licensed asset a cornerstone addition to Teva's specialty portfolio.

Financial terms of the agreement were not disclosed. The deal's success hinges on regulatory pathways in major markets including the United States and European Union, where ocrelizumab biosimilar applications remain under review at respective health authorities.